SEC Form 4 · accession 0000950138-17-000075
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen Patruno Sheehy
Officer — Sr. VP & Chief Compliance Off.
Period of report
Jan 3, 2017
Accepted (ET)
Jan 18, 2017 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 3, 2017 | A | 4,253 | $0.00 | A | 4,253 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Share Options (Right to Buy)F2 | $51.73 | Jan 3, 2017 | A | 11,947 | A | Jan 3, 2018 | Jan 3, 2027 | Common Shares | 11,947 | 11,947 | D |
Explanation of responses
- F1Represents restricted stock units that vest in four equal annual installments beginning January 3, 2018.
- F2The options vest in four equal annual installments beginning January 3, 2018.